Back

Engineering BCMA CAR T cells for myeloma-targeted cargo delivery

Kimman, T.; Cuenca, M.; Slomp, A.; Tieland, R. G.; Rockx-Brouwer, D.; Heijhuurs, S.; Meringa, A. D.; Boschloo, W.; Bosma, D. M.; Kroos, S.; lo Presti, V.; Nierkens, S.; Bovenschen, N.; Kuball, J.; Minnema, M. C.; Sebestyen, Z.; Peperzak, V.

2024-02-17 immunology
10.1101/2024.02.14.580301 bioRxiv
Show abstract

Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, however, primary resistance and relapse after therapy prevent durable remission in a large fraction of cancer patients. One of the underlying causes comprises apoptosis resistance mechanisms in cancer cells that limit killing by CAR T cells. Therefore, we developed a technology that boosts tumor cell apoptosis induced by CAR T cells. We reveal that B cell maturation antigen (BCMA) CAR T cells equipped with a granzyme B-NOXA fusion construct improves killing of multiple myeloma (MM) cells, both in vitro and in a xenograft mouse model, by localizing NOXA to cytotoxic granules that are released into cancer cells upon contact. Since MM cells critically depend on MCL-1 expression, inhibition by its natural ligand NOXA effectively induces apoptosis. Overall, this strategy allows specific delivery of cargo into cancer cells and improves killing efficacy of CAR T cells in a tailor-made manner.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.